Alexion Trial Starts Over Ditched Drug Worth 'Billions'
By Leslie A. Pappas ( July 10, 2023, 8:02 PM EDT) -- Former shareholders of biopharmaceutical company Syntimmune kicked off a five-day trial in Delaware's Court of Chancery Monday with a former board member who testified the biotech's leading drug candidate could have had a market worth "many billions" if Alexion had developed it after buying the company in 2018....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.